The present invention provides an improved system, device, and method for determining a comprehensive state of health in real time using non-invasive patient testing. The invention characterizes disease and other states of health by simultaneously assaying both liquid and gas in a sample or samples. During metabolism, the body performs a large variety of biochemical reactions. Reaction products, reaction by-products, and breakdown products are transported by the circulatory system throughout the body. Many of these molecular products are labile and volatilize into gases from bodily liquids. In gas form, these compounds appear as volatile organic compounds (VOCs).

Embodiments herein relate to medical devices and methods for monitoring and/or treatment including the use of synthetic polymers exhibiting specific binding for compounds such as disease state markers or toxic substances. In an embodiment, a method of testing a patient for a disease state is included, the method can include withdrawing a fluid sample from the patient and contacting the fluid sample with an extracorporeal monitoring device. The extracorporeal monitoring device can include a microporous membrane. The microporous membrane can include a synthetic polymer, wherein the synthetic polymer exhibits binding specificity with a disease state marker. The method can further include evaluating the extracorporeal monitoring device for the presence of the disease state marker. Other embodiments are included herein.

An exercise support apparatus is capable of supporting exercise taken by a patient during blood purification treatment and includes an estimation generating device that generates an estimation representing a circulating-blood-volume rate of change regarding a circulating blood volume that is estimated to be observed after the exercise is started, the estimation being generated after the blood purification treatment is started and from a continuous measurement of the circulating-blood-volume rate of change as regarding changes in circulating blood volume that is conducted before the exercise is started; a calculating device that calculates a difference between a measured value of the circulating-blood-volume rate of change that is acquired after the exercise during the blood purification treatment is started and a value of the estimation generated by the estimation generating device; and a first monitoring device that monitors whether the difference or ratio calculated by the first calculating device is over a predetermined threshold.

Systems and methods for processing sensor data and self-calibration are provided. In some embodiments, systems and methods are provided which are capable of calibrating a continuous analyte sensor based on an initial sensitivity, and then continuously performing self-calibration without using, or with reduced use of, reference measurements. In certain embodiments, a sensitivity of the analyte sensor is determined by applying an estimative algorithm that is a function of certain parameters. Also described herein are systems and methods for determining a property of an analyte sensor using a stimulus signal. The sensor property can be used to compensate sensor data for sensitivity drift, or determine another property associated with the sensor, such as temperature, sensor membrane damage, moisture ingress in sensor electronics, and scaling factors.

Methods for monitoring patient parameters and blood fluid removal system parameters include identifying those system parameters that result in improved patient parameters or in worsened patient parameters. By comparing the patient's past responses to system parameters or changes in system parameters, a blood fluid removal system may be able to avoid future use of parameters that may harm the patient and may be able to learn which parameters are likely to be most effective in treating the patient in a blood fluid removal session.

A system and method for monitoring the health of dialysis patients with Raman spectroscopy measurements of one or more target analytes is described. The methods include irradiating one or more fluids of interest with light to produce one or more spectrum and detecting the spectrum with a detector. The fluids of interest are preferably those related to dialysis, including hemodialysis and peritoneal dialysis. In a preferred embodiment, the fluids are irradiated with monochromatic light, and one or more Raman spectra are detected as a result of the irradiation. The fluids may be irradiated within the dialysis tubing itself, or removed from the dialysis tubing and irradiated in a separate chamber. The Raman spectra of one or more target analytes of a dialysis patient may be followed over time or compared to one or more reference spectra, thereby providing information on the health of dialysis patients.

An apparatus for measuring pressure within a fluid path includes a housing defining the structure of the apparatus. The housing includes a fluid path that extends through the housing and allows a fluid to pass through the housing. The apparatus also includes a first volume chamber that is in fluid communication with the fluid path and has a first volume chamber opening, and a second volume chamber with a second volume chamber opening that is less than the first volume chamber opening. A diaphragm separates the first volume chamber from the second volume chamber and fluidly disconnects the second volume chamber from the fluid path. The diaphragm deforms based upon the pressure within the fluid path. The apparatus also includes an interface that is connectable to a pressure sensor, and the second volume chamber is in fluid communication with the interface.

Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

A hemodialysis system includes: a hemodialysis machine configured to provide hemodialysis treatment to a patient, wherein the hemodialysis treatment includes circulating extracorporeal blood of the patient through an extracorporeal blood circuit; a first oxygen saturation sensor device configured to measure oxygen saturation corresponding to the extracorporeal blood of the patient in the extracorporeal blood circuit; a second oxygen saturation sensor device configured to measure oxygen saturation corresponding to blood flowing within the patient; and at least one controller configured to determine one or more oxygen saturation phase shift (OSPS) values or one or more transcutaneous travel time values corresponding to the patient based on oxygen saturation measurements from the first oxygen saturation sensor device and the second oxygen saturation sensor device.

A system for calculating cardiac output of a patient on an extracorporeal blood oxygenation circuit, such as veno-venous extracorporeal membrane oxygenation, includes determining (i) a first arterial carbon dioxide content or surrogate and (ii) a first carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the first removal rate of carbon dioxide from the blood; establishing a second removal rate of carbon dioxide from the blood in the oxygenator in the extracorporeal blood oxygenation circuit; determining (i) a second arterial carbon dioxide content or surrogate and (ii) a second carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the second removal rate of carbon dioxide from the blood; and calculating a cardiac output of the patient corresponding to a blood flow rate through the extracorporeal blood oxygenation circuit, the first arterial carbon dioxide content or surrogate, the first carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the first removal rate of carbon dioxide from the blood; the second arterial carbon dioxide content or surrogate and the second carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the second removal rate of carbon dioxide from the blood.